All In Biotech

Free tool

FAERS Monitor: Blenrep

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761440 or its brand name (Blenrep, Belantamab Mafodotin-Blmf). Reports on generic versions are filed under their own applications.

Reports

3,107

Serious

2,738

88% of reports

Hospitalization

793

Death reported

1,042

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • keratopathy856
  • visual acuity reduced800
  • death586
  • plasma cell myeloma455
  • dry eye404
  • night blindness317
  • vision blurred204
  • photophobia189
  • foreign body sensation in eyes186
  • ocular toxicity168
  • visual impairment131
  • punctate keratitis130
  • pneumonia126
  • thrombocytopenia124
  • corneal epithelial microcysts122

Reports by year received

View as table
YearReports
20193
2020185
2021776
20221,149
2023270
202482
2025160
2026482

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,052 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
corneal epithelial microcystsSignal12218368.813073.9598,858
keratopathySignal8567977.67273.63,131,953
night blindnessSignal3171670.11484.6422,920
ocular toxicitySignal1681216.11035.8171,909
punctate keratitisSignal1301117.8931.6123,557
foreign body sensation in eyesSignal186203.4176.636,189
visual acuity reducedSignal800167.1157.2128,921
plasma cell myelomaSignal45579.973.335,008
photophobiaSignal18968.759.812,425
dry eyeSignal40455.250.421,335
vision blurredSignal20410.18.81,666
thrombocytopeniaSignal1247.56.3697
visual impairmentSignal1317.26.1692
deathSignal5864.64.31,721
pneumoniaSignal1262.62.2128

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.